| Serial Number | 98173706 |
| Word Mark | ANIVIO |
| Filing Date | Monday, September 11, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, August 12, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 12, 2025 |
| Goods and Services | house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; anti-TNF alpha antibodies for medical purposes; monoclonal antibodies for medical purposes; anti-inflammatories; anti-inflammatory biologic, biosimilar, and pharmaceutical preparations, namely, anti-inflammatory preparations; biologic, biosimilar, and pharmaceutical preparations for the treatment of lung diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of inflammatory disorders; biologic, biosimilar, and pharmaceutical preparations for the treatment of pulmonary sarcoidosis; biologic, biosimilar, and pharmaceutical preparations for the treatment of sarcoidosis; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent granulomas; biologic, biosimilar, and pharmaceutical preparations to reduce or prevent fibrosis; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceutical preparations based on human monoclonal antibodies for the treatment of inflammatory diseases and disorders; pharmaceutical preparations containing self-replicating mRNA for the treatment of lung diseases and disorders, inflammatory disorders, pulmonary sarcoidosis, sarcoidosis; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent granulomas; pharmaceutical preparations containing self-replicating mRNA to reduce or prevent fibrosis |
| Goods and Services | providing medical information; providing health information |
| Goods and Services | research and development of biologics, biosimilars, pharmaceuticals, and self-replicating mRNA; providing information in the field of scientific and medical research related to biologics, biosimilars, pharmaceuticals, and self-replicating mRNA |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, October 1, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, October 1, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, October 1, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Meitheal Pharmaceuticals, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Chicago, IL 60631 |
| Party Name | Meitheal Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Chicago, IL 60631 |
| Event Date | Event Description |
| Thursday, September 14, 2023 | NEW APPLICATION ENTERED |
| Sunday, October 1, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, August 6, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Monday, May 6, 2024 | ASSIGNED TO EXAMINER |
| Monday, May 6, 2024 | NON-FINAL ACTION E-MAILED |
| Monday, May 6, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, May 6, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, August 6, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Wednesday, November 6, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, November 6, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, November 6, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, December 11, 2024 | FINAL REFUSAL E-MAILED |
| Wednesday, December 11, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, June 11, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 11, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Wednesday, December 11, 2024 | FINAL REFUSAL WRITTEN |
| Tuesday, February 25, 2025 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Tuesday, February 25, 2025 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Tuesday, July 8, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 6, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 12, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, August 12, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, June 11, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |